KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intuitive Surgical (ISRG) Cash & Equivalents (2016 - 2025)

Intuitive Surgical (ISRG) has 17 years of Cash & Equivalents data on record, last reported at $3.4 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 66.12% year-over-year to $3.4 billion; the TTM value through Dec 2025 reached $3.4 billion, up 66.12%, while the annual FY2025 figure was $3.4 billion, 66.12% up from the prior year.
  • Cash & Equivalents reached $3.4 billion in Q4 2025 per ISRG's latest filing, up from $2.8 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.6 billion in Q3 2023 and bottomed at $1.1 billion in Q1 2022.
  • Average Cash & Equivalents over 5 years is $2.2 billion, with a median of $2.1 billion recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 134.2% in 2023, then tumbled 32.08% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $1.3 billion in 2021, then rose by 22.49% to $1.6 billion in 2022, then soared by 75.19% to $2.8 billion in 2023, then dropped by 26.81% to $2.0 billion in 2024, then soared by 66.12% to $3.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $3.4 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.0 billion in Q4 2024.